OLUREMI ADEDAPO: Open Payments
NPI 1548770720 · RANDALLSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$593 in 23 payments from 4 companies in 2025. Trend: 2023 $216 · 2024 $313 · 2025 $593
Food & beverage: $593
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $271 |
| ABBVIE INC. | 13 | $152 |
| Axsome Therapeutics, Inc. | 3 | $147 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
Products named: CAPLYTA, VRAYLAR, Auvelity, INGREZZA.
Industry payments across MD — which companies pay providers there.
